FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280495960> ?p ?o ?g. }

• W4280495960 endingPage "1849" @default.
• W4280495960 startingPage "1840" @default.
• W4280495960 abstract "To evaluate the ability of ladarixin (LDX, 400 mg twice-daily for three cycles of 14 days on/14 days off), an inhibitor of the CXCR1/2 chemokine receptors, to maintain C-peptide production in adult patients with newly diagnosed type 1 diabetes.A double-blind, randomized (2:1), placebo-controlled study was conducted in 45 males and 31 females (aged 18-46 years) within 100 days of the first insulin administration. The primary endpoint was the area under the curve (AUC) for C-peptide in response to a 2-hour mixed meal tolerance test (AUC[0-120 min] ) at week 13 ± 1. Secondary endpoints included C-peptide AUC(15-120 min) , HbA1c, daily insulin requirement, severe hypoglycaemic events (SHE), the proportion of subjects achieving HbA1c less than 7.0% without SHE and maintaining a residual beta cell function. Follow-up assessments were scheduled at weeks 13 ± 1, 26 ± 2 and 52 ± 2.In total, 26/26 (100%, placebo) and 49/50 (98%, LDX) patients completed week 13. The mean change from baseline to week 13 in C-peptide AUC(0-120 min) was -0.144 ± 0.449 nmol/L with placebo and 0.003 ± .322 nmol/L with LDX. The difference was not significant (0.149 nmol/L, 95% CI -0.04 to 0.33; P = .122). At week 26, the proportion of patients with HbA1c less than 7.0% without SHE was transiently higher in the LDX group (81% vs. 54%, P = .024). Otherwise, no significant secondary endpoint differences were noted. Transient metabolic benefit was seen at week 26 in favour of the LDX group in the prespecified subpopulation with fasting C-peptide less than the median value at screening.In newly diagnosed patients with type 1 diabetes, short-term LDX treatment had no appreciable effect on preserving residual beta cell function." @default.
• W4280495960 created "2022-05-22" @default.
• W4280495960 creator A5003089036 @default.
• W4280495960 creator A5005129014 @default.
• W4280495960 creator A5009171319 @default.
• W4280495960 creator A5010954807 @default.
• W4280495960 creator A5017456380 @default.
• W4280495960 creator A5030609859 @default.
• W4280495960 creator A5052834144 @default.
• W4280495960 creator A5064447648 @default.
• W4280495960 creator A5064872622 @default.
• W4280495960 creator A5065616204 @default.
• W4280495960 creator A5067754036 @default.
• W4280495960 creator A5070914221 @default.
• W4280495960 creator A5075717817 @default.
• W4280495960 creator A5082541243 @default.
• W4280495960 creator A5087265840 @default.
• W4280495960 date "2022-07-04" @default.
• W4280495960 modified "2023-10-16" @default.
• W4280495960 title "Ladarixin, an inhibitor of the interleukin‐8 receptors <scp>CXCR1</scp> and <scp>CXCR2</scp>, in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial" @default.
• W4280495960 cites W1605318550 @default.
• W4280495960 cites W1970451219 @default.
• W4280495960 cites W1984959662 @default.
• W4280495960 cites W1989870943 @default.
• W4280495960 cites W2055417409 @default.
• W4280495960 cites W2064431167 @default.
• W4280495960 cites W2102751609 @default.
• W4280495960 cites W2109121747 @default.
• W4280495960 cites W2135484010 @default.
• W4280495960 cites W2138589314 @default.
• W4280495960 cites W2149513114 @default.
• W4280495960 cites W2154247668 @default.
• W4280495960 cites W2154694193 @default.
• W4280495960 cites W2166469044 @default.
• W4280495960 cites W2169845440 @default.
• W4280495960 cites W2210893429 @default.
• W4280495960 cites W2519435031 @default.
• W4280495960 cites W2520253181 @default.
• W4280495960 cites W2891250762 @default.
• W4280495960 cites W2900195678 @default.
• W4280495960 cites W2935961302 @default.
• W4280495960 cites W2948104235 @default.
• W4280495960 cites W3099245374 @default.
• W4280495960 cites W3129130281 @default.
• W4280495960 cites W3134851073 @default.
• W4280495960 cites W3135770520 @default.
• W4280495960 cites W3212575051 @default.
• W4280495960 cites W4280495960 @default.
• W4280495960 doi "https://doi.org/10.1111/dom.14770" @default.
• W4280495960 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35589610" @default.
• W4280495960 hasPublicationYear "2022" @default.
• W4280495960 type Work @default.
• W4280495960 citedByCount "12" @default.
• W4280495960 countsByYear W42804959602022 @default.
• W4280495960 countsByYear W42804959602023 @default.
• W4280495960 crossrefType "journal-article" @default.
• W4280495960 hasAuthorship W4280495960A5003089036 @default.
• W4280495960 hasAuthorship W4280495960A5005129014 @default.
• W4280495960 hasAuthorship W4280495960A5009171319 @default.
• W4280495960 hasAuthorship W4280495960A5010954807 @default.
• W4280495960 hasAuthorship W4280495960A5017456380 @default.
• W4280495960 hasAuthorship W4280495960A5030609859 @default.
• W4280495960 hasAuthorship W4280495960A5052834144 @default.
• W4280495960 hasAuthorship W4280495960A5064447648 @default.
• W4280495960 hasAuthorship W4280495960A5064872622 @default.
• W4280495960 hasAuthorship W4280495960A5065616204 @default.
• W4280495960 hasAuthorship W4280495960A5067754036 @default.
• W4280495960 hasAuthorship W4280495960A5070914221 @default.
• W4280495960 hasAuthorship W4280495960A5075717817 @default.
• W4280495960 hasAuthorship W4280495960A5082541243 @default.
• W4280495960 hasAuthorship W4280495960A5087265840 @default.
• W4280495960 hasBestOaLocation W42804959601 @default.
• W4280495960 hasConcept C126322002 @default.
• W4280495960 hasConcept C134018914 @default.
• W4280495960 hasConcept C142724271 @default.
• W4280495960 hasConcept C168563851 @default.
• W4280495960 hasConcept C203092338 @default.
• W4280495960 hasConcept C204787440 @default.
• W4280495960 hasConcept C27081682 @default.
• W4280495960 hasConcept C2777180221 @default.
• W4280495960 hasConcept C555293320 @default.
• W4280495960 hasConcept C71924100 @default.
• W4280495960 hasConcept C76318530 @default.
• W4280495960 hasConcept C90924648 @default.
• W4280495960 hasConcept C98274493 @default.
• W4280495960 hasConceptScore W4280495960C126322002 @default.
• W4280495960 hasConceptScore W4280495960C134018914 @default.
• W4280495960 hasConceptScore W4280495960C142724271 @default.
• W4280495960 hasConceptScore W4280495960C168563851 @default.
• W4280495960 hasConceptScore W4280495960C203092338 @default.
• W4280495960 hasConceptScore W4280495960C204787440 @default.
• W4280495960 hasConceptScore W4280495960C27081682 @default.
• W4280495960 hasConceptScore W4280495960C2777180221 @default.
• W4280495960 hasConceptScore W4280495960C555293320 @default.
• W4280495960 hasConceptScore W4280495960C71924100 @default.
• W4280495960 hasConceptScore W4280495960C76318530 @default.
• W4280495960 hasConceptScore W4280495960C90924648 @default.
• W4280495960 hasConceptScore W4280495960C98274493 @default.

• next